We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

The delay dovetails with moves by Republican lawmakers in at least seven states to ban or limit mRNA vaccines. Some, according to KFF Health News, are also pressing regulators to revoke federal ...

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...

Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.

The agency is sitting on a decision to grant full approval for Novavax’s shot, days after top vaccine regulator pushed out.

Bullish option flow detected in Novavax (NVAX) with 12,673 calls trading, 2x expected, and implied vol increasing almost 14 points to 90.76%.

Shares of Novavax Inc. NVAX slid 6.35% to $5.60 Thursday, on what proved to be an all-around dismal trading session for the ...

Novavax, Inc. (Nasdaq: NVAX) today announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, RPh, has been appointed as his successor. The Company also appointed ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...